WNT5a介导的异常肌动蛋白丝动力学驱动LMNA相关EDMD心脏致病表型
该研究探讨LMNA序列变异导致Emery-Dreifuss肌营养不良(EDMD)心脏病变的分子机制。利用患者来源iPSC-CMs、基因编辑校正株、工程化心脏组织和Lmna L204P敲入小鼠,发现LMNA直接结合WNT5A启动子,变异降低染色质可及性和WNT5A转录,导致WNT5a/RhoA信号失活、肌动蛋白解聚、Cx43转运受损和心律失常;药物激活WNT5a/RhoA或稳定肌动蛋白可挽救表型。
要点
- LMNA变异通过降低WNT5A转录导致WNT5a/RhoA信号失活和肌动蛋白解聚。
- 肌动蛋白解聚引起核膜变形、收缩功能障碍和Cx43转运受损,诱发心律失常。
- 外源性WNT5a、RhoA激活剂或肌动蛋白聚合稳定剂可挽救EDMD iPSC-CMs致病表型。
核心结论
- WNT5a介导的异常肌动蛋白丝动力学是LMNA相关EDMD心脏致病表型的新机制。
- 激活WNT5a/RhoA和稳定肌动蛋白组装可能成为该病的治疗策略。
研究设计与样本
- 研究纳入5例携带LMNA序列变异的临床诊断EDMD患者,用非整合仙台病毒制备iPSC。
- 以2名健康供者来源iPSC为对照,并通过基因组编辑校正LMNA L204P变异生成同基因对照。
- 用单层分化方案生成iPSC-CMs,并构建三维条状力生成人工程化心脏组织。
- 同时生成携带Lmna L204P变异的敲入小鼠模型。
主要发现
- EDMD特异性iPSC-CMs表现出肌节紊乱、核膜结构异常、心律失常和收缩功能障碍。
- 多组学分析显示LMNA直接结合WNT5A启动子,Leu204Pro变异降低染色质可及性和WNT5A转录。
- WNT5a/RhoA信号失活导致EDMD iPSC-CMs中肌动蛋白解聚和聚合抑制。
- 肌动蛋白异常引起核膜变形、收缩功能障碍和Cx43转运受损,Cx43在细胞边界分布减少,促成心律失常表型。
- EDMD工程化心脏组织收缩力生成障碍,RhoA激活剂可显著缓解;Lmna L204P杂合敲入小鼠出现心功能受损和交感应激诱发的心律失常。
关键数值与推荐
- 约20%携带LMNA序列变异的EDMD患者可能最终需要心脏移植。
临床怎么用
- 对于LMNA相关EDMD患者,应关注心律失常和收缩功能障碍的监测。
- WNT5a/RhoA激活或肌动蛋白聚合稳定可能作为潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emery-Dreifuss muscular dystrophy (EDMD) is a rare genetic disorder characterized by early-onset joint contractures, progressive muscle atrophy, and cardiac abnormalities. Patients with EDMD carrying LMNA sequence variations often exhibit severe cardiac manifestations, including frequent atrioventricular block and ventricular tachycardia. Approximately 20% of those patients may ultimately require heart transplantation. The molecular mechanisms by which LMNA sequence variations lead to EDMD remain unknown. METHODS: Five clinically diagnosed patients with EDMD carrying LMNA sequence variations were recruited. Patient-specific induced pluripotent stem cells (iPSCs) were generated using a nonintegrating Sendai virus. Previously generated iPSCs, derived from 2 healthy donors, were used as controls. The LMNA L204P sequence variation was corrected by genome editing in EDMD iPSC lines to generate isogenic controls. All iPSC-derived cardiomyocytes (iPSC-CMs) were generated using a monolayer-based differentiation protocol. Three-dimensional, strip-format, and force-generating human engineered heart tissues were generated from iPSC-CMs. A knock-in mouse model carrying the Lmna L204P sequence variation was also generated. RESULTS: EDMD-specific iPSC-CMs exhibited a variety of deleterious phenotypes, including disorganized sarcomeres, abnormal nuclear envelope structure, arrhythmias, and contractile dysfunction, when compared with control and gene-corrected iPSC-CMs. Multi-omics analysis further revealed that LMNA directly binds the WNT5A promoter and the Leu204Pro sequence variation reduces chromatin accessibility and WNT5A transcription in EDMD iPSC-CMs. WNT5a (Wnt family member 5a)/RhoA (Ras homolog family member A) signaling inactivation was shown to lead to actin depolymerization and inhibition of actin polymerization in EDMD iPSC-CMs. This results in a deformed nuclear envelope, contractile dysfunction, and impaired trafficking of Cx43 (connexin 43). The impairment of Cx43 trafficking causes reduced distribution of Cx43 at cell-cell borders, contributing to the arrhythmic phenotype in EDMD iPSC-CMs. Pharmacological interventions of exogenous WNT5a supplementation, RhoA activator, or an actin polymerization stabilizer effectively rescued the pathogenic phenotypes of EDMD iPSC-CMs. EDMD engineered heart tissues displayed dysfunctional contractile force generation, which was significantly alleviated by RhoA activator. Lmna L204P heterozygous knock-in mice exhibited impaired cardiac function and developed cardiac arrhythmias in response to sympathetic stress. CONCLUSIONS: We present WNT5a-mediated aberrant actin filament dynamics as a novel mechanism underlying cardiac pathogenic phenotypes in LMNA-related EDMD. Our findings indicate that activating WNT5a/RhoA and stabilizing actin assembly may serve as novel therapeutic strategies for this condition.
引用
- Fan H, Wang X, Liu X, et al. WNT5a-Mediated Aberrant Actin Filament Dynamics Drive Cardiac Pathogenic Phenotypes in LMNA-Related Emery-Dreifuss Muscular Dystrophy. Circulation. 2026. PMID: 41993022. doi:10.1161/CIRCULATIONAHA.125.075604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。